Preemptive therapy versus valgancyclovir prophylaxis in cytomegalovirus-positive kidney transplant recipients receiving antithymocyte globulin induction

Transplantation Proceedings

Volumn 44, Issue 9, 2012, Pages 2809-2813

  Couzi, L ^a,b   Helou, S ^a   Bachelet, T ^a,b   Martin, S ^a   Moreau, K ^a   Morel, D ^a   Lafon, M E ^a,b   Garrigue, I ^a,b   Merville, P ^a,b  

^a HÔPITAL PELLEGRIN   (France)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ACUTE GRAFT REJECTION; ADULT; CLINICAL OBSERVATION; CONFERENCE PAPER; CYTOMEGALOVIRUS INFECTION; DRUG EFFICACY; FEMALE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFECTION PREVENTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT DURATION;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTILYMPHOCYTE SERUM; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; CYTOMEGALOVIRUS INFECTIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FRANCE; GANCICLOVIR; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; OPPORTUNISTIC INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84869004881     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2012.09.029     Document Type: Conference Paper

References (50)

1. J.A. Fishman, R.H. Rubin Infection in organ-transplant recipients N Engl J Med 338 1998 1741
2. J.A. Khoury, G.A. Storch, D.L. Bohl Prophylactic versus preemptive oral valganciclovir for the mzrefs;1;gement of cytomegalovirus infection in adult renal transplant recipients. Am J Transplant 6 2006 2134
3. V. Kliem, L. Fricke, T. Wollbrink Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial Am J Transplant 8 2008 975
4. S. Sagedal, K.P. Nordal, A. Hartmann A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients Transplantation 70 2000 1166
5. R.R. Razonable Strategies for managing cytomegalovirus in transplant recipients Expert Opin Pharmacother 11 2010 1983
6. R. Margreiter, J. Klempnauer, P. Neuhaus Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial Am J Transplant 8 2008 1480
7. D. Hernandez, R. Miquel, E. Porrini Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression Transplantation 84 2007 706
8. A.O. Gaber, R.J. Knight, S. Patel A review of the evidence for use of thymoglobulin induction in renal transplantation Transplant Proc 42 2010 1395
9. A.O. Gaber, A.P. Monaco, J.A. Russell Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology Drugs 70 2010 691
10. V. Audard, M. Matignon, F. Hemery Risk factors and long-term outcome of transplant renal artery stenosis in adult recipients after treatment by percutaneous transluminal angioplasty Am J Transplant 6 2006 95
11. S. Pouria, O.I. State, W. Wong CMV infection is associated with transplant renal artery stenosis Qjm 91 1998 185
12. S. Sagedal, K.P. Nordal, A. Hartmann The impact of cytomegalovirus infection and disease on rejection episodes in renal allograft recipients Am J Transplant 2 2002 850
13. O. Toupance, M.C. Bouedjoro-Camus, J. Carquin Cytomegalovirus-related disease and risk of acute rejection in renal transplant recipients: a cohort study with case-control analyses Transpl Int 13 2000 413
14. T. Reischig, P. Jindra, O. Hes Effect of cytomegalovirus viremia on subclinical rejection or interstitial fibrosis and tubular atrophy in protocol biopsy at 3 months in renal allograft recipients managed by preemptive therapy or antiviral prophylaxis Transplantation 87 2009 436
15. J.M. Smith, L. Corey, R. Bittner Subclinical viremia increases risk for chronic allograft injury in pediatric renal transplantation J Am Soc Nephrol 21 2010 1579
16. A. Humar, K.J. Gillingham, W.D. Payne Association between cytomegalovirus disease and chronic rejection in kidney transplant recipients Transplantation 68 1999 1879
17. P.C. Nett, D.M. Heisey, L.A. Fernandez Association of cytomegalovirus disease and acute rejection with graft loss in kidney transplantation Transplantation 78 2004 1036
18. S. Sagedal, A. Hartmann, K.P. Nordal Impact of early cytomegalovirus infection and disease on long-term recipient and kidney graft survival Kidney Int 66 2004 329
19. K.B. Chopra, A.J. Demetris, K. Blakolmer Progression of liver fibrosis in patients with chronic hepatitis C after orthotopic liver transplantation Transplantation 76 2003 1487
20. M.E. Falagas, D.R. Snydman, J. Griffith Exposure to cytomegalovirus from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients Boston Center for Liver Transplantation CMVIG Study Group Clin Infect Dis 23 1996 468
21. M.J. George, D.R. Snydman, B.G. Werner The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients Boston Center for Liver Transplantation CMVIG-Study Group Am J Med 103 1997 106
22. A. Humar, A. Asberg, D. Kumar An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes Am J Transplant 9 2009 374
23. H.Y. Sun, M.M. Wagener, N. Singh Prevention of posttransplant cytomegalovirus disease and related outcomes with valganciclovir: a systematic review Am J Transplant 8 2008 2111
24. D. Lowance, H.H. Neumayer, C.M. Legendre Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group N Engl J Med 340 1999 1462
25. T. Reischig, P. Jindra, O. Hes Valacyclovir prophylaxis versus preemptive valganciclovir therapy to prevent cytomegalovirus disease after renal transplantation Am J Transplant 8 2008 69
26. E.M. Hodson, C.A. Jones, A.C. Webster Antiviral medications to prevent cytomegalovirus disease and early death in recipients of solid-organ transplants: a systematic review of randomised controlled trials Lancet 365 2005 2105
27. A.C. Kalil, J. Levitsky, E. Lyden Meta-analysis: the efficacy of strategies to prevent organ disease by cytomegalovirus in solid organ transplant recipients Ann Intern Med 143 2005 870
28. C.N. Kotton, D. Kumar, A.M. Caliendo International consensus guidelines on the management of cytomegalovirus in solid organ transplantation Transplantation 89 2010 779
29. O. Witzke, I.A. Hauser, M. Bartels Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial Transplantation 93 2012 61
30. J.K. Walker, L.M. Scholz, M.H. Scheetz Leukopenia complicates cytomegalovirus prevention after renal transplantation with alemtuzumab induction Transplantation 83 2007 874
31. H. Weclawiak, N. Kamar, C. Mengelle Pre-emptive intravenous ganciclovir versus valganciclovir prophylaxis for de novo cytomegalovirus-seropositive kidney-transplant recipients Transpl Int 23 2010 1056
32. A. Asberg, A. Humar, H. Rollag Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients Am J Transplant 7 2007 2106
33. A. Humar, M. Michaels American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation Am J Transplant 6 2006 262
34. R.A. Metzger, F.L. Delmonico, S. Feng Expanded criteria donors for kidney transplantation Am J Transplant 3 suppl 4 2003 114
35. K. Solez, R.B. Colvin, L.C. Racusen Banff 07 classification of renal allograft pathology: updates and future directions Am J Transplant 8 2008 753
36. I. Garrigue, A. Doussau, J. Asselineau Prediction of cytomegalovirus (CMV) plasma load from evaluation of CMV whole-blood load in samples from renal transplant recipients J Clin Microbiol 46 2008 493
37. S. Hantz, F. Garnier-Geoffroy, M.C. Mazeron Drug-resistant cytomegalovirus in transplant recipients: a French cohort study J Antimicrob Chemother 65 2010 2628
38. A. Asberg, A.G. Jardine, A.A. Bignamini Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients Am J Transplant 10 2010 1881
39. P. Domagala, A. Kwiatkowski, M. Wszola Complications of transplantation of kidneys from expanded-criteria donors Transplant Proc 41 2009 2970
40. N. Singh Antiviral drugs for cytomegalovirus in transplant recipients: advantages of preemptive therapy Rev Med Virol 16 2006 281
41. I. Helantera, L. Kyllonen, I. Lautenschlager Primary CMV infections are common in kidney transplant recipients after 6 months valganciclovir prophylaxis Am J Transplant 10 2010 2026
42. A.P. Limaye, R. Bakthavatsalam, H.W. Kim Impact of cytomegalovirus in organ transplant recipients in the era of antiviral prophylaxis Transplantation 81 2006 1645
43. S.K. Arthurs, A.J. Eid, R.A. Pedersen Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation Clin Infect Dis 46 2008 840
44. F.L. Luan, M. Kommareddi, A.O. Ojo Impact of cytomegalovirus disease in d+/r- kidney transplant patients receiving 6 months low-dose valganciclovir prophylaxis Am J Transplant 11 2011 1936
45. A. Humar, Y. Lebranchu, F. Vincenti The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients Am J Transplant 10 2010 1228
46. F.L. Luan, M. Kommareddi, A.O. Ojo Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients Transplantation 91 2011 237
47. G. Boivin, N. Goyette, H. Rollag Cytomegalovirus resistance in solid organ transplant recipients treated with intravenous ganciclovir or oral valganciclovir Antivir Ther 14 2009 697
48. A.P. Limaye, L. Corey, D.M. Koelle Emergence of ganciclovir-resistant cytomegalovirus disease among recipients of solid-organ transplants Lancet 356 2000 645
49. J.W. McGillicuddy, N.A. Weimert, D.J. Taber Can preemptive cytomegalovirus monitoring be as effective as universal prophylaxis when implemented as the standard of care in patients at moderate risk? Transplantation 89 2010 1218
50. M.L. Spinner, G. Saab, E. Casabar Impact of prophylactic versus preemptive valganciclovir on long-term renal allograft outcomes Transplantation 90 2010 412